Bruland Home
List of publications
Scientific projects
Selected papers
Curriculum vitae
Latest news
In the media
Web links
Cultural projects
Various activites
Clips & photos
Vintage fishing tackle
File exchange


Professor Øyvind S. Bruland

Professor Øyvind S. Bruland


Cancer therapy with alpha particle emitting radionuclides


The natural bone-seeker Radium-223 is currently in Phase 3 clinical trial in men with hormone-refractory prostate cancer (search Alpharadin as a key word on the front page to access other articles available on this website).

In addition, several other alpha-emitting radionuclides are under development as the effector arm in various targeted cancer therapies.

Click here to view a pdf on this technology platform.




Our Institution has a long-standing interest in the analyses of the biological impact of tumor cells present in peripheral blood and bone marrow aspirates.

Web-link to the various projects and the Steering Committee:

We are particularly interested in two groups of patients:

1. Patients with primary bone sarcomas
2. Prostate cancer patients.

In the first group we have used a technique of immunomagnetic isolation.
This collaboration is with the Department of Tumorbiology.

In the latter cytokeratin staining by standard immuncytochemistry is used.

Bone sarcoma

Click here to view the recent publication in Clinical Cancer Research (pdf-file).

Prostate cancer

You may view the poster (click here) from
Fifth Int. Symposium on Minimal Residual Disease, San Francisco, September 2005

In February 2007 this clinical material was published in Int.J.Cancer:
Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy (Paper in pdf format )

Contact person: Arne Berg MD
Research Fellow, Department Group of Clinical Medicine
University of Oslo
Telephone: 22 93 53 72


A recent paper in the scientific journal Nucelar Medicine and Biology (33; 271-279, 2006) reports the first experiences with a novel alpha-particle based anti CD-20 radioimmunoconjugate.

Radioimmunotherapy has proven clinically effective in patients with non-Hodgkins lymphoma. Trials have so far been performed with beta-emitting isotopes. In contrast to ß-emitters, the shorter range and high linear energy transfer of alpha particles allow for more efficient and selective killing of individually targeted tumor cells. The alpha emitting radioimmunoconjugate 227Th-DOTA-p-benzyl-rituximab is a new potential anti-lymphoma agent that might overcome some of these difficulties is currently in the translational phase of testing. Therapeutic studies in tumor-bearing nude mice will be published soon. The aim is to start clinical Phase-I testing.

Bone-seeking radiopharmaceuticals


ASCO - Prostate Cancer Symposium, San Fransisco

First results from the completed phase 2 study were presented at ASCO - Prostate Cancer Symposium, San Fransisco 23-26/2-06.

Click here to view abstract of presentation and poster

Alpharadin™ reduces PSA and ALP levels significantly in a placebo-controlled trial in prostate cancer patients

Positive results from a Phase II clinical trial of Alpharadin™ based on the alpha particle emitting Radium-223 in patients with hormone-refractory prostate cancer (HRPC) were presented at the Prostate Cancer Foundation's 13th Annual Scientific Retreat (Scottsdale, Arizona, USA, October 19-21, 2006).

Click here to view the poster (pdf format)

Lancet Oncology

223Ra targets skeletal metastases and spares normal tissue

Click for larger image
Lancet Oncology (PDF document)

Our first clinical experiences, a published Phase I study, can be viewed here

Norsk håp om ny kreftmedisin

Et nytt norsk selskap håper å utvikle en medisin som fester seg til kreftceller, og bombarderer dem med radioaktive stråler.

Les artikkel fra Aftenposten her
>> Print this page  [686 visits]